Pricing

Avalo Therapeutics Inc (AVTX)

followers · 1 like
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Garry A. Neil
Employees:
40
540 GAITHER ROAD, SUITE 400, ROCKVILLE, MD, 20850
410-522-8707

Are you looking for this stock instead?

Stock Split History
DateRatio
2022-07-08 1:12
2023-12-29 1:240
Avalo Therapeutics, Inc. discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease and systemic juvenile idiopathic arthritis.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available